Cerevasc has named neurosurgeon Adel Malek as its new chief medical officer. This appointment will allow the company to further accelerate the development and clinical strategy of the eShunt system—a minimally invasive device designed to treat communicating hydrocephalus—according to a press release.
Malek is chief of Neurovascular Surgery, and director of the Cerebrovascular and Endovascular Division, in the Department of Neurosurgery at Tufts Medical Center—and professor of Neurosurgery at Tufts University School of Medicine—in Boston, USA. He is also a co-inventor of the endovascular eShunt device.
His research interests include the study of haemodynamics and mechanotransduction of brain aneurysm development, and advanced three-dimensional imaging to improve the safety of neuroendovascular therapies.
“I am excited about the opportunity to contribute to the great pioneering innovations at Cerevasc as we embark on expanded clinical studies and product development initiatives,” Malek said. “Having worked with the team for the past eight years, I have been impressed with the passion for improving patient care and dedication to transformative innovation, and am looking forward to supporting this important mission.”